A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to
crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC
patients who are treatment nave and to compare lorlatinib to crizotinib with respect to
overall survival in the same population
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.